The 26S proteasome complex: An attractive target for cancer therapy

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1825, Issue 1, 2012, Pages 64-76

  Frankland Searby, Sarah ^a   Bhaumik, Sukesh R ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

26S proteasome complex; Cancers; Proteasome inhibitors

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARFILZOMIB; CELL SURFACE RECEPTOR; CHEMOKINE; DELANZOMIB; DEXAMETHASONE; DNA 26S; DNA DAMAGING AGENT; DOXORUBICIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; LENALIDOMIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MELPHALAN; MNL 9708; MONOCLONAL ANTIBODY; ONX 0912; PR 047; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN KINASE B INHIBITOR; SALINOSPORAMIDE A; STEROID; THALIDOMIDE; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ACUTE LYMPHOCYTIC LEUKEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL ADHESION; CELL CYCLE ARREST; CELL MIGRATION; CHRONIC LYMPHATIC LEUKEMIA; DNA REPAIR; DRUG EFFICACY; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVE SITE; GASTROINTESTINAL TOXICITY; HEART DISEASE; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INJECTION SITE PAIN; LUNG DISEASE; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 81255179936     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2011.10.003     Document Type: Review

References (239)

1. Bhaumik S.R., Malik S. Diverse regulatory mechanisms of eukaryotic transcriptional activation by the proteasome complex. Crit. Rev. Biochem. Mol. Biol. 2008, 43:419-433.
2. Bhaumik S.R. Distinct regulatory mechanisms of eukaryotic transcriptional activation by SAGA and TFIID. Biochim. Biophys. Acta 2011, 1809:97-108.
3. Groll M., Dtizel L., Lowe J., Stock D., Bochtler M., Wolf D.H., Huber R. Structure of the 20S proteasome from yeast at 2.4A resolution. Nature 1997, 386:463-471.
4. Heinemeyer W., Fischer M., Krimmer T., Stachon U., Wolf D.H. The active sites of the eukaryotic 20S proteasome and their involvement in subunit precursor processing. J. Biol. Chem. 1997, 272:25200-25209.
5. Groll M., Heinemeyer W., Jager S., Ulrich T., Bochtler M., Wolf D.H., Huber R. The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:10975-10983.
6. Groll M., Bajorek M., Kohler A., Moroder L., Rubin D.M., Huber R., Glickman M.H., Finley D. A gated channel into the proteasome core particle. Nat. Struct. Biol. 2000, 7:1062-1067.
7. Groll M., Kim K.B., Kairies N., Huber R., Crews C.M. Crystal structure of epoxomicin: 20S proteasome reveals a basis for selectivity of alpha, beta-epoxyketone proteasome inhibitors. J. Am. Chem. Soc. 2000, 122:1237-1238.
8. Navon A., Goldberg A.L. Proteins are unfolded on the surface of the ATPase ring before transport into the proteasome. Mol. Cell 2001, 8:1339-1349.
9. Crawford L.J., Walker B., Irvine A.E. Proteasome inhibitors in cancer therapy. J. Cell Commun. Signal. 2011, 5:101-110.
10. Rock K.L., Goldberg A.L. Degradation of cell proteins and the generation of MHC class 1-presented peptides. Annu. Rev. Immunol. 1999, 17:739-799.
11. Sen R., Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein NFκB by a post-translational mechanism. Cell 1986, 47:921-928.
12. Pajonk F., McBride W.H. The proteasome in cancer biology and treatment. Radiat. Res. 2001, 156:447-459.
13. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
14. Montagut C., Rovira A., Albanell J. The proteasome: a novel target for anticancer therapy. Clin. Transl. Oncol. 2006, 8:313-317.
15. Luqman B.S., Pezzuto J.M. NFkappaB: a promising target for natural products in cancer chemoprevention. Phytother. Res. 2010, 24:949-963.
16. Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS 541 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001, 361:5071-5076.
17. Sunwoo J.B., Chen Z., Dong G., et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear-factor kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 2001, 7:1419-1428.
18. Cusack J.C., Liu R., Houston M., et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear-factor-kappaB inhibition. Cancer Res. 2001, 61:3535-3540.
19. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., et al. Phase I trial of the proteasome inhibitor PS 341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 2002, 20:4420-4427.
20. Cortes J., Thomas D., Koller C., et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin. Cancer Res. 2004, 10:3371-3376.
21. Ditsworth D., Zong W.X. NF-kappaB: key mediator of inflammation-associated cancer. Cancer Biol. Ther. 2004, 3:1214-1216.
22. McCarty M.F. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr. Cancer Ther. 2004, 3:349-380.
23. Sarkar F.H., Li Y. Cell signaling pathways altered by natural chemopreventive agents. Mutat. Res. 2004, 555:53-64.
24. Reddy G.P., Barrack E.R., Dou Q.P., Menon M., Pelley R., Sarkar F.H., Sheng S. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer. J. Cell. Biochem. 2006, 98:1408-1423.
25. Aggarwal B.B. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004, 6:203-208.
26. Monks N.R., Biswas D.K., Pardee A.B. Blocking antiapoptosis as a strategy for cancer chemotherapy: NFkappaB as a target. J. Cell. Biochem. 2004, 92:646-650.
27. Gilmore T.D., Koedood M., Piffat K.A., White D.W. Rel/NFκB/IκB proteins and cancer. Oncogene 1996, 13:1367-1378.
28. Gilmore T.D. NFκB: from basic research to human disease. Oncogene 2006, 51:6679-6899.
29. Perkins N.D. Integrating cell-signaling pathways with NFκB and IKK function. Nat. Rev. Mol. Cell Biol. 2007, 8:40-62.
30. McConkey D.J., Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. Updat. 2008, 11:164-179.
31. Momand J., Jung D., Wilczynski S., Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998, 26:3452-3459.
32. Scheffner M., Wemess B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1136.
33. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75:495-505.
34. Vaziri S.A., Grabowski D.R., Hill J., Rybicki L.R., Burk R., Bukowski R.M., Ganapathi M.K., Gamapathi R. Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 and VHL independent. Anticancer. Res. 2009, 29:2961-2969.
35. Ding W.X., Ni H.M., Chen X., Yu J., Zhang L., Yin X.M. A coordinated action of Bax, PUMA and p53 promotes MG-132-induced mitochondria activation and apoptosis in colon cancer cells. Mol. Cancer Ther. 2007, 6:1062-1069.
36. Qin J.Z., Ziffra J., Stennett L., Bodner B., Bonish B.K., Chaturvedi V., Bennett F., Pollock P.M., Trent J.M., Hendrix M.J., Rizzo P., Miele L., Nickoloff B.J. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 2005, 65:6282-6293.
37. Williams S.A., McConkey D.J. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 cancer cells. Cancer Res. 2003, 63:7338-7344.
38. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13:1501-1512.
39. Chu I.M., Hengst L., Joyce M. The CDK inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 2008, 8:253-267.
40. Inui N., Kitagawa K., Miwa S., Hattori T., Chida K., Nakamura H., Kitagawa M. High expression of Cks1 in human nonsmall cell lung carcinoma. Biochem. Biophys. Res. Commun. 2003, 303:978-984.
41. Lu Z., Hunter T. Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors. Cell Cycle 2010, 9:2342-2352.
42. Xu H., Zhang Z., Li M., Zhang R. MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change. J. Biol. Chem. 2010, 285:18407-18414.
43. Wang B., Liu K., Lin H.Y., Bellam N., Ling S., Lin W.C. 14-3-3Tau regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer. Mol. Cell. Biol. 2010, 30:1508-1527.
44. Fung T.K., Poon R.Y. A roller coaster ride with the mitotic cyclins. Semin. Cell Dev. Biol. 2005, 16:335-342.
45. Mitra J., Enders G.H., Azizkhan-Clifford J., Lengel K.L. Dual regulation of the anaphase promoting complex in human cells by cyclin A-Cdk2 and cyclin A-Cdk1 complexes. Cell Cycle 2006, 5:661-666.
46. van Leuken R., Clijsters L., Wolthuis R. To cell cycle, swing the APC/C. Biochim. Biophys. Acta 2008, 1786:49-59.
47. Glotzer M., Murray A.W., Kirschner M.W. Cyclin is degraded by the ubiquitin pathway. Nature 1991, 349:132-138.
48. Amon A., Irniger S., Nasmyth K. Closing the cell cycle circle in yeast: G2 cyclin proteolysis initiated at mitosis persists until the activation of G1 cyclins in the next cycle. Cell 1994, 77:1037-1050.
49. Brandeis M. The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase. EMBO J. 1996, 15:5280-5289.
50. Keyomarsi K., Pardee A.B. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:1112-1116.
51. Gialmanidis I.P., Bravou V., Amanetopoulou S.G., Varakis J., Kourea H., Papadaki H. Overexpression of hedgehog pathway molecules and FOXM1 in non-small cell lung carcinomas. Lung Cancer 2009, 66:64-74.
52. Bektas N., Haaf A., Veeck J., Wild P.J., Luscher-Firzlaff J., Hartmann A., Knuchel R., Dahl E. Tight correlation between expression of the Forkhead transcription factor FoxM1 and Her2 in human breast cancer. BMC Cancer 2008, 8:42.
53. Yoshida Y., Wang I.C., Yoder H.M., Davidson N.O., Costa R.H. The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. Gastroenterology 2007, 132:1420-1431.
54. Liu M., Dai B., Kang S.H., Ban K., Huang F.J., Lang F.F., Aldape K.D., Xie T.X., Pelloski C.E., Xie K., Sawaya R., Huang S. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res. 2006, 66:3593-3602.
55. Wang Z., Banerjee S., Kong D., Li Y., Sarker F.H. Downregulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 2007, 67:8293-8300.
56. Gemenetzidas E., Bose A., Riaz A.M., Chaplin T., Young B.D., Ali M., Sugden D., Thurlow J.K., Cheong S.C., Teo S.H., Wan H., Waseem A., Parkinason E.K., Fortune F., The M.T. FoxM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS One 2009, 4:e4849.
57. Bhat U.G., Halasi M., Gartel A.L. FoxM1 is a general target for proteasome inhibitors. PLoS One 2009, 4:e6593.
58. Gartel A.L. A new target for proteasome inhibitors: FoxM1. Expert Opin. Investig. Drugs 2010, 19:235-242.
59. Obeng E.A., Carlson L.M., Gutman D.M., Harrington W.J., Lee K.P., Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107:4907-4916.
60. Nawrocki S.T., Carwe J.S., Pino M.S., Highshaw R.A., Dunner K., Huang P., Abbruzzese J.L., McConkey D.J. Bortezomib sensitizes pancreatic cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res. 2005, 65:11658-11666.
61. Fribley A., Wang C.Y. Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol. Ther. 2006, 5:745-748.
62. Morgillo F., D'Aiuto E., Troiani T., MArtinelli E., Cascone T., De Palma R., Orditura M., De Vita F., Ciardiello F. Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors. Lung Cancer 2011, 71:283-290.
63. Jaworski T. Degradation and beyond: control of androgen receptor activity by the proteasome system. Cell. Mol. Biol. Lett. 2006, 11:109-131.
64. Kinyamu H.K., Collins J.B., Grissom S.F., Hebbar P.B., Archer T.K. Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition. Mol. Carcinog. 2008, 47:845-885.
65. Powers G.L., Ellison-Zelski S.J., Casa A.J., Lee A.V., Alarid E.T. Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer. Oncogene 2010, 29:1509-1518.
66. Rossi D., Zlotnik A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 2000, 18:217-242.
67. Belperio J.A., Keane M.P., Arenberg D.A., Addison C.L., Ehlert J.E., Burdick M.D., Strieter R.M. CXC chemokines in angiogenesis. J. Leukoc. Biol. 2000, 68:1-8.
68. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
69. Peterson F.C., Thorpe J.A., Harder A.G., Volkman B.F., Schwarze S.R. Structural determinants involved in the regulation of CXCL14/BRAK expression by the 26S proteasome. J. Mol. Biol. 2006, 363:813-822.
70. Schwarze S.R., Luo J., Isaacs W.B., Jarrard D.F. Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate 2005, 64:67-74.
71. Shurin G.V., Ferris R.L., Tourkova I.L., Perez L., Lokshin A., Balkir L., Collins B., Chatta G.S., Shurin M.R. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J. Immunol. 2005, 174:5490-5498.
72. Shellenberger T.D., Wang M., Gujrati M., Jayakumar A., Strieter R.M., Burdick M.D., Ioannides C.G., Efferson C.L., El-Naggar A.K., Roberts D., Clayman G.L., Frederick M.J. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res. 2004, 64:8262-8270.
73. Fushimi T., O'Connor T.P., Crystal R.G. Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth. Cancer Res. 2006, 66:3513-3522.
74. Sepp Lorenzino L., Ma Z., Lebwohl D.E., Vinitsky A., Rosen N. Herbimycin A induces the 20S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. J. Biol. Chem. 1995, 270:16580-16587.
75. Philip P.A., Harris A.L. Potential for protein kinase C inhibitors in cancer therapy. Cancer Treat. Res. 1995, 78:3-27.
76. Lee H.W., Smith L., Pettit G.R., Vinitsky A., Smith J.B. Ubiquitination of protein kinase C-alpha and degradation by the proteasome. J. Biol. Chem. 1996, 271:20973-20976.
77. Hou D., Cenciarelli C., Jensen J.P., Nguygen H.B., Weissman A.M. Activation-dependent ubiquitination of a T cell antigen receptor subunit on multiple intracellular lysines. J. Biol. Chem. 1994, 269:14244-14247.
78. Mori S., Kanaki H., Tanaka K., Morisaki N., Saito Y. Ligand-activated platelet-derived growth factor beta-receptor is degraded through proteasome-dependent proteolytic pathway. Biochem. Biophys. Res. Commun. 1995, 217:224-229.
79. Treier M., Staszewski L.M., Bohmann D. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 1994, 78:787-798.
80. Tsurumi C., Ishida N., Tamura T., Kakizuka A., Nishida E., Okumura E., Kishimoto T., Inagaki M., Okazaki K., Sagata N., Ishihara A., Tanaka K. Degradation of c-Fos by the 26S proteasome is accelerated by c-Jun and multiple protein kinases. Mol. Cell. Biol. 1995, 15:5682-5687.
81. Jariel-Encontre I., Pariat M., Martin F., Carillo S., Salvat C., Piechaczyk M. Ubiquitinylation is not an absolute requirement for degradation of c-Jun protein by the 26S proteasome. J. Biol. Chem. 1995, 270:11623-11627.
82. Hermida-Matsumoto M.L., Chock P.B., Curran T., Yang D.C. Ubiquitinylation of transcription factors c-Jun and c-Fos using reconstituted ubiquitinylating enzymes. J. Biol. Chem. 1996, 271:4930-4936.
83. Musti A.M., Treier M., Bohmann D. Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science 1997, 275:400-402.
84. Spataro V., Norbury C., Harris A.L. The ubiquitin-proteasome pathway in cancer. Br. J. Cancer 1998, 77:448-455.
85. Schreiber M., Baumann B., Cotton M., Angel P., Wagner E.F. Fos is an essential component of the mammalian UV response. EMBO J. 1995, 14:5338-5349.
86. Pinkus R., Weiner L.M., Daniel V. Role of oxidants and antioxidants in the induction of AP- I, NF-kappaB, and glutathione S-transferase gene expression. J. Biol. Chem. 1996, 271:13422-13429.
87. Moffat G.J., McLaren A.W., Wolf C.R. Involvement of Jun and Fos proteins in regulating transcriptional activation of the human pi class glutathione S-transferase gene in multidrug-resistant MCF7 breast cancer cells. J. Biol. Chem. 1994, 269:16397-16402.
88. Ritke M.K., Bergoltz V.V., Allan W.P., Yalowich J.C. Increased c-jun/AP-1 levels in etoposide-resistant human leukemia K562 cells. Biochem. Pharmacol. 1994, 48:525-533.
89. Yao K.S., Godwin A.K., Johnson S.W., Ozols R.F., O'Dwyer P.J., Hamilton T.C. Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res. 1995, 55:4367-4374.
90. Motegi A., Murakawa Y., Takeda S. The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy. Cancer Lett. 2009, 283:1-9.
91. Belich M.P., Glynne R.J., Senger G., Sheer D., Trowsdale J. Proteasome components with reciprocal expression to that of the MHC-encoded LMP proteins. Curr. Biol. 1994, 4:769-776.
92. Fruh K., Gossen M., Wang K., Bujard H., Peterson P.A., Yang Y. Displacement of housekeeping proteasome subunits by MHC-encoded LMPs: a newly discovered mechanism for modulating the multicatalytic proteinase complex. EMBO J. 1994, 13:3236-3244.
93. Groettrup M., Kraft R., Kostka S., Standera S., Stohwasser R., Kloetzel P.M. A third interferon-gamma-induced subunit exchange in the 20S proteasome. Eur. J. Immunol. 1996, 26:863-869.
94. Hisamatsu H., Shimbara N., Saito Y., Kristensen P., Hendil K.B., Fujiwara T., Takahashi E., Tanahashi N., Tamura T., Ichihara A., Tanaka K. Newly identified pair of proteasomal subunits regulated reciprocally by interferon gamma. J. Exp. Med. 1996, 183:1807-1816.
95. Nandi D., Jiang H., Monaco J.J. Identification of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit. J. Immunol. 1996, 156:2361-2364.
96. Gaczynska M., Goldberg A.L., Tanaka K., Hendil K.B., Rock K.L. Proteasome subunits X and Y alter peptidase activities in opposite ways to the interferon-gamma-induced subunits LMP2 and LMP7. J. Biol. Chem. 1996, 271:17275-17280.
97. Kuckelkom U., Frentzel S., Kraft R., Kostka S., Groettrup M., Klbetzel P.M. Incorporation of major histocompatibility complex-encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-gamma. Eur. J. Immunol. 1995, 25:2605-2611.
98. Restifo N.P., Esquivel F., Kawakami Y., Yewdell J.W., Mule J.J., Rosenberg S.A., Bennink J.R. Identification of human cancers deficient in antigen processing. J. Exp. Med. 1993, 177:265-272.
99. Sibille C., Gould K.G., Willard Gallo K., Thomson S., Rivett A.J., Powis S., Butcher G.W., De Baetselier P. LMP2+ proteasomes are required for the presentation of specific antigens to cytotoxic T lymphocytes. Curr. Biol. 1995, 5:923-930.
100. Rotem Yehudar R., Groettrup M., Soza A., Kloetzel P.M., Ehrlich R. LMP-associated proteolytic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. J. Exp. Med. 1996, 183:499-514.
101. Seliger B., Hohne A., Knuth A., Bemhard H., Meyer T., Tampe R., Momburg F., Huber C. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res. 1996, 56:1756-1760.
102. Matsui M., Machida S., Itani-Yohda T., Akatsuka T. Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-gamma. J. Gastroenterol. Hepatol. 2002, 17:897-907.
103. Pan J., Zhang Q., Wang Y., You M. 26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro. PLoS One 2010, 5:e13298.
104. Leffers N., Gooden M.J., Mokhova A.A., Kast W.M., Boezen H.M., Ten Hoor K.A., Hollema H., Daemen T., van der Zee A.G., Nijman H.W. Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer. Gynecol. Oncol. 2009, 113:256-263.
105. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 2000, 18:621-663.
106. Karin M., Cao Y., Greten F.R., Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2002, 2:301-310.
107. Tergaonkar V., Pando M., Vafa O., Wahl G., Verma I. p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 2002, 1:493-503.
108. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Fanourakis G., Gu X., et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:14374-14379.
109. LeBlanc R., Catley L.P., Hideshima T., Lentzsch S., Mitsiades C.S., Mitsiades N., et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002, 62:4996-5000.
110. Hideshima T., Mitsiades C., Akiyama M., Hayashi T., Chauhan D., Richardson P., et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003, 101:1530-1534.
111. Nakanishi C., Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 2005, 5:297-309.
112. Piva R., Belardo G., Santoro M.G. NF-kappaB: a stress-regulated switch for cell survival. Antioxid. Redox Signal. 2006, 8:478-486.
113. Chauhan D., Hideshima T., Anderson K.C. Targeting proteasomes as therapy in multiple myeloma. Adv. Exp. Med. Biol. 2008, 615:251-260.
114. Mukherjee S., Raje N., Schoonmaker J.A., Liu J.C., Hideshima T., Wein M.N., et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J. Clin. Invest. 2008, 118:491-504.
115. Anderson K.C. Oncogenomics to target myeloma in the bone marrow microenvironment. Clin. Cancer Res. 2011, 17:1225-1233.
116. Pagano M., Tam S.W., Theodoras A.M., et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269:682-685.
117. Bloom J., Amador V., Bartolini F., DeMartino G., Pagano M. Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell 2003, 115:71-82.
118. Piva R., Ruggeri B., Williams M., Costa G., Tamagno I., Ferrero D., Giai V., Coscia M., Peola S., Massaia M., Pezzoni G., Allievi C., Pescalli N., Cassin M., di Giovine S., Nicoli P., de Feudis P., Strepponi I., Roato I., Ferracini R., Bussolati B., Camussi G., Jones-Bolin S., Hunter K., Zhao H., Neri A., Palumbo A., Berkers C., Ovaa H., Bernareggi A., Inghirami G. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacological profile competitive with bortezomib. Blood 2008, 111:2765-2775.
119. Nawrocki S.T., Bruns C.J., Harbison M.T., et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol. Cancer Ther. 2002, 1:1243-1253.
120. Adams J. The proteasome as a novel target for the treatment of breast cancer. Breast Dis. 2002, 15:61-70.
121. Williams S., Pettaway C., Song R., Papandreou C., Logothetis C., McConkey D.J. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol. Cancer Ther. 2003, 2:835-843.
122. Fribley A., Zeng Q., Wang C.Y. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol. Cell. Biol. 2004, 24:9695-9704.
123. Yu C., Rahmani M., Dent P., Grant S. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp. Cell Res. 2004, 295:555-566.
124. Chen D., Frezza M., Schmitt S., Kanwar J., P Dou Q. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr. Cancer Drug Targets 2011, 11:239-253.
125. Scagliotti G. Proteasome inhibitors in lung cancer. Crit. Rev. Oncol. Hematol. 2006, 58:177-189.
126. Perez-Galan P., Roue G., Villamor N., Montserrat E., Campo E., Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006, 107:257-264.
127. Nalepa G., Rolfe M., Harper J.W. Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov. 2006, 5:596-613.
128. Ludwig H., Khayat D., Giaccone G., Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005, 104:1794-1807.
129. Kuhn D.J., Chen Q., Voorhees P.M., Strader J.S., Shenk K.D., Sun C.M., Demo S.D., Bennett M.K., van Leeuwen F.W., Chanan-Khan A.A., Orlowski R.Z. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin proteasome pathway against preclinical models of multiple myeloma. Blood 2007, 110:3281-3290.
130. de Bettignies G., Coux O. Proteasome inhibitors: dozens of molecules and still counting. Biochimie 2010, 92:1530-1545.
131. Kessler B.M., Tortorella D., Altun M., et al. Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits. Chem. Biol. 2001, 8:913-929.
132. Aggarwal B.B., Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 2006, 71:1397-1421.
133. Chen D., Landis-Piwowar K.R., Chen M.S., Dou Q.P. Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts. Breast Cancer Res. 2007, 9:R80.
134. Birt D.F., Mitchell D., Gold B., Pour P., Pinch H.C. Inhibition of ultraviolet light induced skin carcinogenesis in SKH-1 mice by apigenin, a plant flavonoid. Anticancer. Res. 1997, 17:85-91.
135. Gupta S., Afaq F., Mukhtar H. Involvement of nuclear factorkappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. Oncogene 2002, 21:3727-3738.
136. Chen D., Daniel K.G., Chen M.S., Kuhn D.J., Landis-Piwowar K.R., Dou Q.P. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem. Pharmacol. 2005, 69:1421-1432.
137. Zheng P.W., Chiang L.C., Lin C.C. Apigenin induced apoptosis through p53-dependent pathway in human cervical carcinoma cells. Life Sci. 2005, 76:1367-1379.
138. Liu L.Z., Fang J., Zhou Q., Hu X., Shi X., Jiang B.H. Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol. Pharmacol. 2005, 68:635-643.
139. Choi J.S., Choi Y.J., Park S.H., Kang J.S., Kang Y.H. Flavones mitigate tumor necrosis factor-alpha-induced adhesion molecule upregulation in cultured human endothelial cells: role of nuclear factor-kappa B. J. Nutr. 2004, 134:1013-1019.
140. Sim G.S., Lee B.C., Cho H.S., Lee J.W., Kim J.H., Lee D.H., Pyo H.B., Moon D.C., Oh K.W., Yun Y.P., et al. Structure activity relationship of antioxidative property of flavonoids and inhibitory effect on matrix metalloproteinase activity in UVA-irradiated human dermal fibroblast. Arch. Pharm. Res. 2007, 30:290-298.
141. Chen D., Chen M.S., Cui Q.C., Yang H., Dou Q.P. Structure-proteasome-inhibitory activity relationships of dietary flavonoids in human cancer cells. Front. Biosci. 2007, 12:1935-1945.
142. Horinaka M., Yoshida T., Shiraishi T., Nakata S., Wakada M., Sakai T. The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol. Cancer Ther. 2006, 5:945-951.
143. Nam S., Smith D.M., Dou Q.P. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J. Biol. Chem. 2001, 276:13322-13330.
144. Pajonk F., Riedisser A., Henke M., McBride W.H., Fiebich B. The effects of tea extracts on proinflammatory signaling. BMC Med. 2006, 4:28.
145. Xu B., Monsarrat B., Gairin J.E., Girbal-Neuhauser E. Effect of ajoene, a natural antitumor small molecule, on human 20S proteasome activity in vitro and in human leukemic HL60 cells. Fundam. Clin. Pharmacol. 2004, 18:171-180.
146. Hassan H.T. Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy. Leuk. Res. 2004, 28:667-671.
147. Bernstein L.R. Mechanisms of therapeutic activity for gallium. Pharmacol. Rev. 1998, 50:665-682.
148. Einhorn L. Gallium nitrate in the treatment of bladder cancer. Semin. Oncol. 2003, 30:34-41.
149. Jakupec M.A., Keppler B.K. Gallium in cancer treatment. Curr. Top. Med. Chem. 2004, 4:1575-1583.
150. Straus D.J. Gallium nitrate in the treatment of lymphoma. Semin. Oncol. 2003, 30:25-33.
151. Chitambar C.R. Apoptotic mechanisms of gallium nitrate: basic and clinical investigations. Oncology (Hunting.) 2004, 18:39-44.
152. Chen D., Frezza M., Shakya R., Cui Q.C., Milacic V., Verani C.N., Dou Q.P. Inhibition of the proteasome activity by gallium(III) complexes contributes to their anti prostate tumor effects. Cancer Res. 2007, 67:9258-9265.
153. Chitambar C.R., Seligman P.A. Effects of different transferrin forms on transferrin receptor expression, iron uptake, and cellular proliferation of human leukemic HL60 cells. Mechanisms responsible for the specific cytotoxicity of transferrin-gallium. J. Clin. Invest. 1986, 78:1538-1546.
154. Esserman L., Takahashi S., Rojas V., Warnke R., Levy R. An epitope of the transferrin receptor is exposed on the cell surface of high-grade but not low-grade human lymphomas. Blood 1989, 74:2718-2729.
155. Chitambar C.R. Gallium compounds as antineoplastic agents. Curr. Opin. Oncol. 2004, 16:547-552.
156. Adams J., Behnke M., Chen S., et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 1998, 8:333-338.
157. Bogyo M., Gaczynska M., Ploegh H.L. Proteasome inhibitors and antigen presentation. Biopolymers 1997, 43:269-280.
158. Groll M., Koguchi Y., Huber R., Kohno J. Crystal structure of the 20S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor. J. Mol. Biol. 2001, 311:543-548.
159. Meng L., Kwok B.H., Sin N., et al. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res. 1999, 59:2798-2801.
160. Fenteany G., Standaert R.F., Lane W.S., et al. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by 3' lactacystin. Science 1995, 268:726-731.
161. Kozlowski L., Stoklosa T., Omura S., et al. Lactacystin inhibits cathepsin A activity in melanoma cell lines. Tumour Biol. 2001, 22:211-215.
162. Adams J., Palombella V.J., Sausville E.A., Johnson J., Destree A., Lazarus D.D., Maas J., Pien C.S., Prakash S., Elliott P.J. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999, 59:2615-2622.
163. Kisselev A.F., Goldberg A.L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 2001, 8:739-758.
164. Aghajanian C., Soignet S., Dizon D.S., et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 2002, 8:2505-2511.
165. Papandreou C.N., Daliani D.D., Nix D., et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol. 2004, 22:2108-2121.
166. Portnow J., Frankel P., Koehler S., Twardowski P., Shibata S., Martel C., Morgan R., Cristea M., Chow W., Lim D., Chung V., Reckamp K., Leong L., Synold T.W. A phase I study of bortezomib and temozolomide in patients with advanced solid tumors. Cancer Chemother. Pharmacol. Aug 18 2011, (Epub ahead of print).
167. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348:2609-2617.
168. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 2005, 352:2487-2498.
169. Russo S.M., Tepper J.E., Baldwin A.S., et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-nB. Int. J. Radiat. Oncol. Biol. Phys. 2001, 50:183-193.
170. An W.G., Hwang S.G., Trepel J.B., Blagosklonny M.V. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000, 14:1276-1283.
171. Kumar A., Hozo I., Wheatley K., Djulbegovic B. Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review. Am. J. Hematol. 2011, 86:18-24.
172. Papandreou C.N., Logothetis C.J. Bortezomib as a potential treatment for prostate cancer. Cancer Res. 2004, 64:5036-5043.
173. Kane R.C., Farell A.T., Sridhara R., Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin. Cancer Res. 2006, 12:2955-2960.
174. Kane R.C., Dagher R., Farell A., Ko C.W., Sridhara R., Justice R., Pazdur R. Bortezomib for the treatment of mantle cell lymphoma. Clin. Cancer Res. 2007, 13:5291-5294.
175. Ma M.H., Yang H.H., Parker K., et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 2003, 9:1136-1144.
176. Orlowski R.Z., Nagler A., Sonneveld P., et al. The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed/refractory multiple myeloma compared with bortezomib alone: results from a randomized phase 3 study. J. Clin. Oncol. 2007, 25:3892-3901.
177. Mitsiades N., Mitsiades C.S., Richardson P.G., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003, 101:2377-2380.
178. Roué G., Pérez-Galán P., Mozos A., López-Guerra M., Xargay-Torrent S., Rosich L., Saborit-Villarroya I., Normant E., Campo E., Colomer D. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood 2011, 117:1270-1279.
179. Pérez-Galán P., Dreyling M., Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011, 117:26-38.
180. Fribley A.M., Evenchik B., Zeng Q., Park B.K., Guan J.Y., Zhang H., Hale T.J., Soengas M.S., Kaufman R.J., Wang C.Y. Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J. Biol. Chem. 2006, 281:31440-31447.
181. McConkey D.J., Dinney C.P. The molecular, the bad, and the ugly: preventing bladder cancer via mTOR inhibition. Cancer Prev. Res. (Phila.) 2009, 2:1001-1002.
182. Zhu K., Dunner K., McConkey D.J. Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene 2010, 29:451-462.
183. Janku F., McConkey D.J., Hong D.S., Kurzrock R. Autophagy as a target for anticancer therapy. Nat. Rev. Clin. Oncol. 2011, 8:528-539.
184. Yew E.H., Cheung N.S., Choy M.S., Qi R.Z., Lee A.Y., Peng Z.F., Melendez A.J., Manikandan J., Koay E.S., Chiu L.L., Ng W.L., Whiteman M., Kandiah J., Halliwell B. Proteasome inhibition by lactacystin in primary neuronal cells induces both potentially neuroprotective and pro-apoptotic transcriptional responses: a microarray analysis. J. Neurochem. 2005, 94:943-956.
185. Mulligan G., Mitsiades C., Bryant B., Zhan F., Chng W.J., Roels S., Koenig E., Fergus A., Huang Y., Richardson P., Trepicchio W.L., Broyl A., Sonneveld P., Shaughnessy J.D., Bergsagel P.L., Schenkein D., Esseltine D.L., Boral A., Anderson K.C. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007, 109:3177-3188.
186. Poulaki V., Mitsiades C.S., Kotoula V., Negri J., McMillin D., Miller J.W., Mitsiades N. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro. Invest. Ophthalmol. Vis. Sci. 2007, 48:4706-4719.
187. Chauhan D., Hideshima T., Anderson K.C. Targeting proteasome as a therapy in multiple myeloma. Programmed Cell Death in Cancer Progression and Therapy 2008, 251-260. Springer, (Chapter 12). R. Khosravi-Far, E. Whilte (Eds.).
188. Tang Z.Y., Wu Y.L., Gao S.L., Shen H.W. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells. J. Surg. Res. 2008, 145:111-123.
189. Zhao X., Qiu W., Kung J., Zhao X., Peng X., Yegappan M., Yen-Lieberman B., His E.D. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies. Leuk. Res. 2008, 32:275-285.
190. Brüning A., Burger P., Vogel M., Rahmeh M., Friese K., Lenhard M., Burges A. Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis. Invest. New Drugs 2009, 27:543-551.
191. Wang Q., Mora-Jensen H., Weniger M.A., Perez-Galan P., Wolford C., Hai T., Ron D., Chen W., Trenkle W., Wiestner A., Ye Y. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2200-2205.
192. Milani M., Rzymski T., Mellor H.R., Pike L., Bottini A., Generali D., Harris A.L. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Res. 2009, 69:4415-4423.
193. Armstrong J.L., Flockhart R., Veal G.J., Lovat P.E., Redfern C.P. Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells. J. Biol. Chem. 2010, 285:6091-6100.
194. Brüning A., Vogel M., Mylonas I., Friese K., Burges A. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by Nelfinavir. Curr. Cancer Drug Targets Jul 15 2011, (Epub ahead of print).
195. Yang Y., Ikezoe T., Saito T., Kobayashi M., Koeffler H.P., Taguchi H. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci. 2004, 95:176-180.
196. Lauricella M., Emanuele S., D'Anneo A., Calvaruso G., Vassallo B., Carlisi D., Portanova P., Vento R., Tesoriere G. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways. Apoptosis 2006, 11:607-625.
197. Chen Z., Ricker J.L., Malhotra P.S., Nottingham L., Bagain L., Lee T.L., Yeh N.T., Van Waes C. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms. Mol. Cancer Ther. 2008, 7:1949-1960.
198. Rzymski T., Milani M., Singleton D.C., Harris A.L. Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle 2009, 8:3838-3847.
199. Wottawa M., Köditz J., Katschinski D.M. Normoxic destabilization of ATF-4 depends on proteasomal degradation. Acta Physiol. (Oxf.) 2010, 198:457-463.
200. Chauhan D., Li G., Shringarpure R., Podar K., Ohtake Y., Hideshima T., Anderson K.C. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 2003, 63:6174-6177.
201. Papageorgiou A., Kamat A., Benedict W.F., Dinney C., McConkey D.J. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol. Cancer Ther. 2006, 5:3032-3041.
202. Uttamsingh V., Lu C., Miwa G., Gan L. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6 and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab. Dispos. 2005, 33:1723-1728.
203. Venkatakrishnan K., Rader M., Ramanathan R.K., Ramalingam S., Chen E., Riordan W., Trepicchio W., Cooper M., Karol M., von Moltke L., Neuwirth R., Egorin M., Chatta G. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, twoway crossover drug-drug interaction study. Clin. Ther. 2009, 31:2444-2458.
204. Cavaletti G., Jakubowiak A.J. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk. Lymphoma 2010, 51:1178-1187.
205. Dispenzieri A. Bortezomib for myeloma - much ado about something. N. Engl. J. Med. 2005, 352:2546-2548.
206. Oakervee H.E., Popat R., Curry N., et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br. J. Haematol. 2005, 129:755-762.
207. Sacco A., Aujay M., Morgan B., Azab A.K., Maiso P., Liu Y., Zhang Y., Azab F., Ngo H.T., Issa G.C., Quang P., Roccaro A.M., Ghobrial I.M. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. Clin. Cancer Res. 2011, 17:1753-1764.
208. Demo S.D., Kirk C.J., Aujay M.A., Buchholz T.J., Dajee M., Ho M.N., Jiang J., Laidig G.J., Lewis E.R., Parlati F., Shenk K.D., Smyth M.S., Sun C.M., Vallona M.K., Woo T.M., Molineaux C.J., Bennett M.K. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007, 67:6383-6391.
209. Jain S., Diefenbach C., Zain J., O'Connor O.A. Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. Core Evid. 2011, 6:43-57.
210. Khan M.L., Stewart A.K. Carfilzomib: a novel second-generation proteasome inhibitor. Future Oncol. 2011, 7:607-612.
211. Dasmahapatra G., Lembersky D., Son M.P., Attkisson E., Dent P., Fisher R.I., Friedberg J.W., Grant S. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol. Cancer Ther. 2011, 10:1686-1697.
212. Yang J., Wang Z., Fang Y., Jiang J., Zhao F., Wong H., Bennett M.K., Molineaux C.J., Kirk C.J. Pharmacokinetics, pharmacodynamics, metabolism, distribution and excretion of carfilzomib in rats. Drug Metab. Dispos. 2011, 39:1873-1882.
213. Demo E., Frush D., Gottfried M., et al. Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?. J. Hepatol. 2007, 46:492-498.
214. Dasmahapatra G., Lembersky D., Kramer L., Fisher R.I., Friedberg J., Dent P., Grant S. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 2010, 115:4478-4487.
215. Fuchs O., Provaznikova D., Marinov I., Kuzelova K., Spika I. Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells. Cardiovasc. Hematol. Disord. Drug Targets 2009, 9:62-77.
216. Roccaro A.M., Sacco A., Aujay M., Ngo H.T., Azab A.K., Quang P., Maiso P., Runnels J., Anderson K.C., Demo S., Ghobrial I.M. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood 2010, 115:4051-4060.
217. Zhou H.J., Aujay M.A., Bennett M.K., Dajee M., Demo S.D., Fang Y., Ho M.N., Jiang J., Kirk C.J., Laidig G.J., Lewis E.R., Lu Y., Muchamuel T., Parlati F., Ring E., Shenk K.D., Shields J., Shwonek P.J., Stanton T., Sun C.M., Sylvain C., Woo T.M., Yang J. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J. Med. Chem. 2009, 52:3028-3038.
218. Chauhan D., Singh A.V., Aujay M., Kirk C.J., Bandi M., Ciccarelli B., Raje N., Richardson P., Anderson K.C. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 2010, 116:4906-4915.
219. Cusack J.C., Liu R., Xia L., Chao T.H., Pien C., Niu W., Palombella V.J., Neuteboom S.T., Palladino M.A. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin. Cancer Res. 2006, 12:6758-6764.
220. Feling R.H., Buchanan G.O., Mincer T.J., Kauffman C.A., Jensen P.R., Fenical W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew. Chem. Int. Ed. Engl. 2003, 42:355-357.
221. Macherla V.R., Mitchell S.S., Manam R.R., Reed K.A., Chao T.H., Nicholson B., Deyanat-Yazdi G., Mai B., Jensen P.R., Fenical W.F., Neuteboom S.T., Lam K.S., Palladino M.A., Potts B.C. Structure-activity relationaship studies of salinosporamide A (NPI-0052), a novel marine-derived proteasome inhibitor. J. Med. Chem. 2005, 48:3684-3687.
222. Miller C.P., Ban K., Dujka M.E., McConkey D.J., Munsell M., Palladino M., Chandra J. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007, 110:267-277.
223. Chauhan D., Catley L., Li G., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005, 8:407-419.
224. Roccaro A.M., Leleu X., Sacco A., Jia X., Melham M., Moreau A.S., Ngo H.T., Runnels J., Azab A., Azab F., Burwick N., Farag M., Treon S.P., Palladino M.A., Hideshima T., Chauhan D., Anderson K.C., Ghobrial I.M. Dual targeting of the proteasome regulates survival and homing in Waldenstrommacroglobulinemia. Blood 2008, 111:4752-4763.
225. Miller C.P., Rudra S., Keating M.J., Wierda W.G., Palladino M., Chandra J. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood 2009, 113:4289-4299.
226. Ruiz S., Krupnik Y., Keating M., Chandra J., Pallidino M., McConkey D. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol. Cancer Ther. 2006, 5:1836-1843.
227. Baritaki S., Chapman A., Yeung K., Spandidos D.A., Palladino M., Bonavida B. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor NPI-0052: pivitol roles of Snail repression and RKIP induction. Oncogene 2009, 28:3573-3585.
228. Sloss C.M., Wang F., Liu R., Xia L., Houston M., Ljungman D., Palladino M.A., Cusack C.J. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin. Cancer Res. 2008, 14:5116-5123.
229. Singh A.V., Palladino M.A., Lloyd G.K., Potts B.C., Chauhan D., Anderson K.C. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. Br. J. Haematol. 2010, 149:550-559.
230. Dorsey B.D., Iqbal M., Chatterjee S., Menta E., Bernardini R., Bernareggi A., Cassara P.G., D'Arasmo G., Ferretti E., De Munari S., Oliva A., Pezzoni G., Allievi C., Strepponi I., Ruggeri B., Ator M.A., Williams M., Mallamo J.P. Discovery of a potent, selective and orally active proteasome inhibitor for the treatment of cancer. J. Med. Chem. 2008, 51:1068-1072.
231. Sanchez E., Li M., Steinberg J.A., Wang C., Shen J., Bonavida B., Li Z.W., Chen H., Berenson J.R. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphelan. Br. J. Haematol. 2010, 148:569-581.
232. Chauhan D., Tian Z., Zhou B., Kuhn D.J., Orlowski R.Z., Raje N.S., Richardson P.G., Anderson K.C. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin. Cancer Res. 2011, 17:5311-5321.
233. Kupperman E., Lee E.C., Cao Y., Bannerman B., Fitzgerald M., Berger A., Yu J., Yang Y., Hales P., Bruzzese F., Liu J., Blank J., Garcia K., Tsu C., Dick L., Fleming P., Yu L., Manfredi M., Rolfe M., Bolen J. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010, 70:1970-1980.
234. Muchamuel T., Basler M., Aujay M.A., Suzuki E., Kalim K.W., Lauer C., Sylvain C., Ring E.R., Shields J., Jiang J., Shwonek P., Parlati F., Demo S.D., Bennett M.K., Kirk C.J., Groettrup M. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat. Med. 2009, 15:781-787.
235. Basler M., Dajee M., Moll C., Groettrup M., Kirk C.J. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J. Immunol. 2010, 185:634-641.
236. Palombella V.J., Conner E.M., Fuseler J.W., Destree A., Davis J.M., Laroux F.S., Wolf R.E., Huang J., Brand S., Elliott P.J., Lazarus D., McCormack T., Parent L., Stein R., Adams J., Grisham M.B. Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15671-15676.
237. Qureshi N., Perera P.Y., Shen J., Zhang G., Lenschat A., Splitter G., Morrison D.C., Vogel S.N. The proteasome as a lipopolysaccharide-binding protein in macrophages: differential effects of proteasome inhibition on lipopolysaccharide-induced signaling events. J. Immunol. 2003, 171:1515-1525.
238. Singh A.V., Bandi M., Aujay M.A., Kirk C.J., Hark D.E., Raje N., Chauhan D., Anderson K.C. PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br. J. Haematol. 2010, 152:155-163.
239. Kuhn D.J., Hunsucker S.A., Chen Q., Voorhees P.M., Orlowski M., Orlowski R.Z. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 2009, 113:4667-4776.